Cassava Sciences (SAVA) 10-K 6 Feb 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Jan. 19, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Trading Symbol	PTIE
Entity Registrant Name	PAIN THERAPEUTICS INC
Entity Central Index Key	1,069,530
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,595,509
Entity Public Float			$ 22,840,436
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 10,479	$ 16,615
Marketable securities		2,099
Other current assets	184	356
Total current assets	10,663	19,070
Property and equipment, net	156	232
Other assets	12
Total assets	10,831	19,302
Current liabilities:
Accounts payable	424	303
Accrued development expense	399	27
Accrued compensation and benefits	309	335
Total current liabilities	1,132	665
Noncurrent liabilities
Total liabilities	1,132	665
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.001 par value; 10,000,000 shares authorized, none issued and outstanding
Common stock, $.001 par value; 120,000,000 shares authorized; 6,595,509 and 6,591,705 shares issued and outstanding at December 31, 2017 and 2016, respectively	7	7
Additional paid-in capital	167,091	164,118
Accumulated other comprehensive income
Accumulated deficit	(157,399)	(145,488)
Total stockholders' equity	9,699	18,637
Total liabilities and stockholders' equity	$ 10,831	$ 19,302

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	6,595,509	6,591,705
Common stock, shares outstanding	6,595,509	6,591,705

Statements Of Operations

Statements Of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating expenses:
Research and development	$ 7,615	$ 9,176
General and administrative	4,334	5,781
Total operating expenses	11,949	14,957
Operating loss	(11,949)	(14,957)
Interest income	38	107
Net loss	$ (11,911)	$ (14,850)
Net loss per share, basic and diluted	$ (1.82)	$ (2.28)
Shares used in computing net loss per share, basic and diluted	6,537	6,520

Statements Of Comprehensive Inc

Statements Of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Statements Of Comprehensive Income (Loss) [Abstract]
Net loss	$ (11,911)	$ (14,850)
Other comprehensive income (loss):
Net unrealized gains (losses) on marketable securities
Comprehensive loss	$ (11,911)	$ (14,850)

Statements Of Stockholders' Equ

Statements Of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2015	$ 7	$ 159,998	$ (130,638)	$ 29,367
Balance, Shares at Dec. 31, 2015	6,536,588
Stock options for employees		3,467		3,467
Stock options for non-employees		25		25
Performance Awards and related non-cash stock-related compensation		842		842
Performance Awards and related non-cash stock-related compensation, shares	69,286
Performance Awards related to statutory taxes		(214)		(214)
Performance Awards related to statutory taxes, shares	(14,169)
Net loss			(14,850)	(14,850)
Balance at Dec. 31, 2016	$ 7	164,118	(145,488)	18,637
Balance, Shares at Dec. 31, 2016	6,591,705
Stock options for employees		2,954		2,954
Stock options for non-employees		19		$ 19
Issuance of common stock pursuant to exercise of stock options, shares	3,804
Net loss			(11,911)	$ (11,911)
Balance at Dec. 31, 2017	$ 7	$ 167,091	$ (157,399)	$ 9,699
Balance, Shares at Dec. 31, 2017	6,595,509

Statements Of Cash Flows

Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (11,911)	$ (14,850)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash stock-based compensation	2,973	4,334
Depreciation and amortization	68	58
Non-cash net interest income	(2)	(8)
Changes in operating assets and liabilities:
Other current assets	172	86
Other non-current assets	(12)	12
Accounts payable	129	(711)
Accrued development expense	372	(867)
Accrued compensation and benefits	(26)	(288)
Net cash used in operating activities	(8,237)	(12,234)
Cash flows from investing activities:
Purchases of property and equipment		(75)
Purchases of marketable securities	(399)	(4,141)
Sales of marketable securities	400
Maturities of marketable securities	2,100	2,050
Net cash provided (used in) investing activities	2,101	(2,166)
Cash flows from financing activities:
Cash used for statutory taxes for net exercise of Performance Awards		(214)
Deferred financing costs		(70)
Net cash used in financing activities		(284)
Net decrease in cash and cash equivalents	(6,136)	(14,684)
Cash and cash equivalents at beginning of period	16,615	31,299
Cash and cash equivalents at end of period	$ 10,479	$ 16,615

General And Liquidity

General And Liquidity	12 Months Ended
	Dec. 31, 2017
General And Liquidity [Abstract]
General And Liquidity	1. General and Liquidity  Pain Therapeutics, Inc. develops proprietary drugs that offer significant improvements to patients and healthcare professionals. We generally focus our drug development efforts on disorders of the nervous system, such as chronic pain.  On November 16, 2016, we received a letter from the Listing Qualifications staff of Nasdaq (the “Staff”) notifying us that, for the previous 30 consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement (the “Minimum Price Requirement”) under Nasdaq’s Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), if during the 180 calendar days following the date of the notification, or prior to May 15, 2017, the closing bid price of our common stock is at or above $1.00 for a minimum of 10 consecutive business days, the Staff will provide us with written confirmation of compliance. On May 24, 2017, we received a letter from the Staff indicating that we had regained compliance with the $1.00 minimum closing bid requirement following completion of the reverse stock split described below.  On May 4, 2017, following stockholder approval, our board of directors approved a reverse stock split at a ratio of 7 -for-1. On May 4, 2017, we filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect the 7-for-1 reverse stock split of our outstanding shares of common stock. The number of outstanding shares of common stock on the date of the reverse split was reduced from 46.1 million to 6.6 million shares. Our common stock began trading on the Nasdaq Global Market on a split-adjusted basis when the market opened for trading on May 10, 2017. As a result, all common stock share amounts included in these consolidated financial statements have been retroactively reduced by a factor of seven, and all common stock per share amounts have been increased by a factor of seven, with the exception of our common stock par value.  Liquidity  The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $157 million at December 31, 2017. We expect our cash requirements to be significant in the future. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our drug candidates and the resources we devote to researching and developing, formulating, manufacturing, commercializing and supporting our products. We may seek additional future funding through public or private financing within this timeframe, if such funding is available and on terms acceptable to us. 

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	2. Summary of Significant Accounting Policies  Use of Estimates  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.  Proceeds from Grants  In 2017, we received $1.4 million in research grants from the NIH and NIDA and $1.5 million in 2016 . We record the proceeds from the grant as a reduction to our research and development expenses.  Cash Equivalents, Marketable Securities and Concentration of Credit Risk  We invest in cash equivalents and marketable securities. We consider highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Our marketable securities include interest-bearing financial instruments, generally consisting of corporate or government securities.  Our investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. We maintain our investments at one financial institution.  A change in prevailing interest rates may cause the fair value of the investment to fluctuate. We do not recognize an impairment charge related to this type of fluctuation because the fluctuation is temporary and eliminated by the time an investment matures. We would recognize an impairment charge if and when we determine that a decline in the fair value below the amortized cost of an investment is other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery.  We may elect to sell marketable securities before they mature. We hold these investments as “available for sale” and include these investments in our Balance Sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year.  Fair Value Measurements  We report our cash equivalents and marketable securities at fair value as Level 1, Level 2 or Level 3 using the following inputs: · Level 1 includes quoted prices in active markets. We base the fair value of money market funds and U.S. treasury securities on Level 1 inputs. · Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. We use market pricing and other observable market inputs obtained from third-party providers. We use the bid price to establish fair value where a bid price is available. We base the fair value of our marketable securities on Level 2 inputs. · Level 3 includes unobservable inputs that are supported by little or no market activity. We do not have any investments where the fair value is based on Level 3 inputs.  We include unrealized gains or losses on our investments as Accumulated other comprehensive income (loss) in the Stockholders’ equity section of our Balance Sheets. We include changes in net unrealized gains or losses in our Statements of Comprehensive Income (Loss). We would recognize significant realized gains and losses on a specific identification basis as other income in our Statements of Operations.  Business Segments  We report segment information based on how we internally evaluate the operating performance of our business units, or segments. Our operations are confined to one business segment: the development of novel drugs.  Stock-based Compensation  We recognize non-cash expense for the fair value of all stock options and other share-based awards. We use the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. For options granted to employees and directors, we recognize the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four years. For options granted to non-employees, we remeasure the fair value expense using Black-Scholes each reporting period.  We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. We multiply the number of Performance Awards by the fair market value of our common stock on the date of grant to calculate the fair value of each award. We estimate an implicit service period for achieving performance criteria for each award. We recognize the resulting fair value as expense over the implicit service period when we conclude that achieving the performance criteria is probable. We periodically review and update as appropriate our estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.  Net Loss per Share  Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding equity awards and warrants. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands):     Years ended December 31,  2017 2016  Numerator:  Net loss $ (11,911) $ (14,850)  Denominator:  Shares used in computing net loss per share, basic and diluted 6,537 6,520  Net loss per share, basic and diluted $ (1.82) $ (2.28)  Dilutive common shares excluded from net loss per share, diluted 2,497 2,535   We excluded weighted equity awards outstanding to purchase common stock from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.  Income Taxes  We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year.  We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance.  We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our Statement of Operations in that period.  We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.  Recent Accounting Pronouncements  We reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.  In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . This ASU provides guidance on statement of cash flows presentation for eight specific cash flow issues where diversity in practice exists. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company expects that the adoption will not have a material impact on its financial statements.  In February 2016, the FASB issued ASU No. 2016-02 , Leases (Topic 842) . The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For operating leases, a lessee is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating the effect that the adoption of this ASU will have on its financial statements. The Company currently expects that its operating lease commitment will be subject to the new standard and recognized as right-of-use asset and operating lease liability upon adoption of ASU 2016-02, which will increase the total assets and total liabilities that it reports relative to such amounts prior to adoption. 

Collaboration Agreements

Collaboration Agreements	12 Months Ended
	Dec. 31, 2017
Collaboration Agreements [Abstract]
Collaboration Agreements	3. Collaboration Agreements  Durect Corporation  We have an exclusive, worldwide Development and License Agreement, or the Durect Agreement, with Durect to use a patented controlled-release technology that forms the basis for REMOXY. Under the terms of the Durect Agreement, we are solely responsible for clinical development, Durect is responsible for furnishing suitable laboratory facilities, equipment and personnel during pre-clinical phases of development and we and Durect are jointly responsible for certain pre-clinical activities. We reimburse Durect’s expenses and have made milestone payments based on the achievement of certain clinical or regulatory milestones.

Cash And Cash Equivalents And M

Cash And Cash Equivalents And Marketable Securities	12 Months Ended
	Dec. 31, 2017
Cash And Cash Equivalents And Marketable Securities [Abstract]
Cash And Cash Equivalents And Marketable Securities	4. Cash and Cash Equivalents and Marketable Securities  Cash, cash equivalents and marketable securities held as available-for-sale consisted of the following (in thousands ):     Cash, Cash Equivalents and Marketable Securities  Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Accrued Interest Total Value  December 31, 2017  Cash $ 158 $ — $ — $ 158 $ — $ 158  Cash equivalents 10,321 — — 10,321 — 10,321  Total cash and cash equivalents $ 10,479 $ — $ — $ 10,479 $ — $ 10,479  Reported as:  Cash and cash equivalents $ 10,479 — — $ 10,479 $ — $ 10,479  Marketable securities — — — — — —  $ 10,479 $ — $ — $ 10,479 $ — $ 10,479  Maturities:  Matures in one year or less $ 10,479 $ — $ — $ 10,479 $ — $ 10,479  Matures one to three years — — — — — —  $ 10,479 $ — $ — $ 10,479 $ — $ 10,479   December 31, 2016  Cash $ 1,434 $ — $ — $ 1,434 $ — $ 1,434  Cash equivalents 12,783 — — 12,783 — 12,783  Commercial paper 4,497 — — 4,497 — 4,497  Total cash and cash equivalents $ 18,714 $ — $ — $ 18,714 $ — $ 18,714  Reported as:  Cash and cash equivalents $ 16,615 — — $ 16,615 $ — $ 16,615  Marketable securities 2,099 — — 2,099 — 2,099  $ 18,714 $ — $ — $ 18,714 $ — $ 18,714  Maturities:  Matures in one year or less $ 18,714 $ — $ — $ 18,714 $ — $ 18,714  Matures one to three years — — — — — —  $ 18,714 $ — $ — $ 18,714 $ — $ 18,714   To date we have no t recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.  Our assets measured at fair value were (in thousands ):     Level 1 Level 2 Level 3 Total  December 31, 2017  Cash and cash equivalents $ 10,479 $ — $ — $ 10,479  Commercial paper — — — —  $ 10,479 $ — $ — $ 10,479  December 31, 2016  Cash and cash equivalents $ 14,217 $ — $ — $ 14,217  Commercial paper — 4,497 — 4,497  $ 14,217 $ 4,497 $ — $ 18,714 

Property And Equipment

Property And Equipment	12 Months Ended
	Dec. 31, 2017
Property And Equipment [Abstract]
Property And Equipment	5. Property and Equipment  Property and equipment includes furniture and equipment with a purchase value of $1.0 million at December 31, 2017 and 2016. Depreciation is recognized using the straight-line method over the expected life of the property and equipment. Accumulated depreciation was $0.8 million at December 31, 2017 and $0.7 million at December 31, 2016.

Stockholders' Equity And Stock-

Stockholders' Equity And Stock-Based Compensation	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity And Stock-Based Compensation [Abstract]
Stockholders' Equity And Stock-Based Compensation	6. Stockholders' Equity and Stock-Based Compensation  Preferred Stock  Our Board of Directors has the authority to issue preferred stock in one or more series and to fix the rights, preferences, privileges, restrictions and the number of shares constituting any series or the designation of the series.  2008 Equity Incentive Plan  Under our 2008 Equity Incentive Plan, or 2008 Equity Plan, our employees, directors and consultants receive d share-based awards, including grants of stock options and Performance Awards. Our Board of Directors or a designated Committee of the Board is responsible for administration of the 2008 Equity Plan and determine d the terms and conditions of each option granted, consistent with the terms of the plan. The 2008 Equity Plan expired in December 201 7. S hare-based awards generally expire ten years from the date of grant.  When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. We then use our cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.  Stock Options  The following summarizes information about stock option activity during 2017:    Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value  In years In millions  Outstanding as of December 31, 2016 2,435,249 $ 25.19 4.8 $ —  Options granted 1,026,410 $ 3.68  Options exercised — $ —  Options forfeited/canceled (479,504) 31.73  Outstanding as of December 31, 2017 2,982,155 $ 16.74 6.2 $ 0.4  Vested and expected to vest at December 31, 2017 2,982,155 $ 16.74 6.2 $ 0.4  Exercisable at December 31, 2017 1,757,688 $ 24.02 4.1 $ —   The following summarizes information about stock options at December 31, 2017 by a range of exercise prices:    Options outstanding Options exercisable  Weighted  average Weighted Weighted  Number of remaining average Number of average  Range of exercise prices outstanding contractual exercise vested exercise  From To options life (in years) price options price  $ 3.24 $ 4.09 933,200 9.8 $ 3.59 46,458 $ 3.25  $ 4.10 $ 15.61 620,243 7.5 $ 11.63 345,168 $ 12.51  $ 16.31 $ 23.38 628,411 3.9 $ 19.05 597,399 $ 19.16  $ 23.59 $ 35.00 656,841 2.9 $ 30.41 626,841 $ 30.24  $ 36.40 $ 53.55 143,460 3.4 $ 51.66 141,822 $ 51.82  2,982,155 6.2 $ 16.74 1,757,688 $ 24.02  We use Black-Scholes to estimate the fair value of options granted. Black-Scholes considers a number of factors, including the market price of our common stock. For options granted to employees and directors, we used certain factors to value each stock option granted, which resulted in a weighted average fair value of options granted during 2017 and 2016, as follows:     2017 2016  Volatility 79% to 83% 72%  Risk-free interest rates 2% to 2.4% 1% to 2%  Expected life of option 7 years 7 years  Dividend yield zero zero  Forfeiture rate zero zero  Weighted average fair value of stock options granted $2.74 $1.60   Volatility is based on reviews of the historical volatility of our common stock. Risk-free interest rates are based on yields of U.S. treasury notes in effect at the date of grant. Expected life of option is based on actual historical option exercises. Dividend yield is zero because we do not anticipate paying cash dividends in the foreseeable future. We estimate forfeitures and adjust this estimate periodically based in part on the extent to which actual forfeitures differ from our estimates.  For options granted to non-employees, we estimate the fair value of stock options granted using factors similar to those used for stock options granted to employees and directors and appropriate for the terms underlying the stock options granted to non-employees. We re-measure the compensation expense for options granted to non-employees each reporting period.  As of December 31, 2017, we expect to recognize compensation expense of $ 5.3 million related to non-vested options held by employees and directors over the weighted average remaining recognition period of 3.2 years.  Performance Awards  The following summarizes information about Performance Award activity during 2017:    Number of Performance Awards  Outstanding as of December 31, 2016 222,060  Granted —  Vested Performance Awards —  Forfeited/Canceled (69,720)  Outstanding as of December 31, 2017 152,340   If and when outstanding Performance Awards vest, we would recognize $ 2.5 million in non-cash stock-based compensation expense. These Performance Awards expire between 2022 and 2026 .  Stock-Based Compensation Expense  The following summarizes information about non-cash stock-based compensation expense, in thousands :     Years ended December 31,  2017 2016   Research and development  Vesting of stock options $ 1,205 $ 1,313  Vesting of Performance Awards — 438  1,205 1,751  General and administrative  Vesting of stock options 1,768 2,179  Vesting of Performance Awards — 404  1,768 2,583  Total non-cash stock-based compensation expenses  Vesting of stock options 2,973 3,492  Vesting of Performance Awards — 842  $ 2,973 $ 4,334   Non-cash stock-related compensation expense related to vesting of Performance Awards was associated with the resubmission of the NDA for REMOXY. 

Employee 401(k) Benefit Plan

Employee 401(k) Benefit Plan	12 Months Ended
	Dec. 31, 2017
Employee 401(k) Benefit Plan [Abstract]
Employee 401(k) Benefit Plan	7. Employee 401(k) Benefit Plan  We have a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code. The plan covers substantially all employees. Employees are eligible to participate in the plan the first day of the month after hire and may contribute up to the current statutory limits under Internal Revenue Service regulations. The 401(k) plan permits us to make additional matching contributions on behalf of all employees. Through December 31, 201 7 , we have not made any matching contributions to the 401(k) plan.  

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Income Taxes	8. Income Taxes  U.S. Tax Reform On December 22, 2017, legislation commonly known as the Tax Cuts and Jobs Act, or the Act, was signed in to law. The Tax Act, among other changes, reduces the U.S. federal corporate tax rate from 35% to 21% , requires taxpayers to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. On December 31, 2017, the Company did not have any foreign subsidiaries and the international aspects of the Tax Act are not applicable. In connection with the initial analysis of the impact of the Tax Act, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally 21%. The remeasurement of the Company's deferred tax balance was primarily offset by application of its valuation allowance. The Company is still in the process of analyzing the impact to the Company of the Tax Act. Where the Company has been able to make reasonable estimates of the effects for which its analysis is not yet complete, the Company has recorded provisional amounts. Where the Company has not yet been able to make reasonable estimates of the impact of certain elements, the Company has not recorded any amounts related to those elements and has continued accounting for them in accordance with ASC 740 on the basis of the tax laws in effect immediately prior to the enactment of the Tax Act. We did not provide for income taxes in 2017 and 2016 because we had a net operating loss for tax purposes in those years and the tax benefit that would have resulted from the statutory rate was fully offset by the valuation allowance.  Deferred tax assets and valuation allowance  Deferred tax assets reflect the tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. We reduced our deferred taxes assets at December 31, 2017 for the reduced corporate tax rate to 21% in recently enacted tax legislations. We offset our deferred tax assets by a valuation allowance because we are uncertain about the timing and amount of any future profits. Significant components of our deferred tax assets are as follows (in thousands ):    December 31,  2017 2016  Deferred tax assets:  Net operating loss carryforwards $ 15,600 $ 22,300  Stock-related compensation 5,300 9,100  Research & development credit carryforwards 6,400 6,200  Other 200 200  27,500 37,800  Valuation allowance (27,500) (37,800)  $ — $ —   As of the beginning of 2017, we increased both our net operating loss carryforwards and our valuation allowance by $0.9 million when we adopted ASU 2016-09 for certain tax deductions associated with stock option transactions greater than the stock-related compensation expense in our financial statements. The valuation allowance decreased by $10.3 million in 2017 and increased by $3.6 million in 2016.  Our pre-tax net operating loss carryforwards of $74 million are federal and expire between 2029 and 2036 . As of December 31, 2017, we had federal research and development tax credits of approximately $10.7 million , which expire in the years 2023 through 2036 .  Unrecognized tax benefits  We have unrecognized tax benefits related to tax credits. We added to our unrecognized tax benefits in 201 7 and 201 6 as follows (in thousands ):     2017 2016  Beginning balance $ 4,200 $ 4,000  Additions based on tax positions related to the current year 100 200  Ending balance $ 4,300 $ 4,200 

Leases And Commitments

Leases And Commitments	12 Months Ended
	Dec. 31, 2017
Leases And Commitments [Abstract]
Leases And Commitments	9. Leases and Commitments  We lease approximately 6,000 square feet of office space pursuant to a non-cancelable operating lease in Austin, TX that expires in December 2020 . Future minimum lease payments are (in thousands) .      2018 2019 2020 Total  Minimum lease payments $ 91 $ 95 $ 99 $ 285   We believe that our facilities are adequate and suitable for our current needs. Rent expense was $0.1 million both in 2017 and 2016.  We conduct our product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. We have contractual arrangements with these organizations, however these contracts are cancelable on thirty days’ notice and our obligations under these contracts are largely based on services performed.

Summary Of Significant Accoun17

Summary Of Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Use of Estimates	Use of Estimates  The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. Actual results could differ from those estimates.
Proceeds from Grants	Proceeds from Grants  In 2017, we received $1.4 million in research grants from the NIH and NIDA and $1.5 million in 2016 . We record the proceeds from the grant as a reduction to our research and development expenses.
Cash Equivalents, Marketable Securities and Concentration of Credit Risk	Cash Equivalents, Marketable Securities and Concentration of Credit Risk  We invest in cash equivalents and marketable securities. We consider highly-liquid financial instruments with original maturities of three months or less to be cash equivalents. Our marketable securities include interest-bearing financial instruments, generally consisting of corporate or government securities.  Our investment policy allows for investments in marketable securities with active secondary or resale markets, establishes diversification and credit quality requirements and limits investments by maturity and issuer. We maintain our investments at one financial institution.  A change in prevailing interest rates may cause the fair value of the investment to fluctuate. We do not recognize an impairment charge related to this type of fluctuation because the fluctuation is temporary and eliminated by the time an investment matures. We would recognize an impairment charge if and when we determine that a decline in the fair value below the amortized cost of an investment is other-than-temporary. We consider various factors in determining whether to recognize an impairment charge, including any adverse changes in the investees’ financial condition, how long the fair value has been below the amortized cost and whether it is more likely than not that we would elect to or be required to sell the marketable security before its anticipated recovery.  We may elect to sell marketable securities before they mature. We hold these investments as “available for sale” and include these investments in our Balance Sheets as current assets, even though the contractual maturity of a particular investment may be beyond one year.
Fair Value Measurements	Fair Value Measurements  We report our cash equivalents and marketable securities at fair value as Level 1, Level 2 or Level 3 using the following inputs: · Level 1 includes quoted prices in active markets. We base the fair value of money market funds and U.S. treasury securities on Level 1 inputs. · Level 2 includes significant observable inputs, such as quoted prices for identical or similar investments, or other inputs that are observable and can be corroborated by observable market data for similar securities. We use market pricing and other observable market inputs obtained from third-party providers. We use the bid price to establish fair value where a bid price is available. We base the fair value of our marketable securities on Level 2 inputs. · Level 3 includes unobservable inputs that are supported by little or no market activity. We do not have any investments where the fair value is based on Level 3 inputs.  We include unrealized gains or losses on our investments as Accumulated other comprehensive income (loss) in the Stockholders’ equity section of our Balance Sheets. We include changes in net unrealized gains or losses in our Statements of Comprehensive Income (Loss). We would recognize significant realized gains and losses on a specific identification basis as other income in our Statements of Operations.
Business Segments	Business Segments  We report segment information based on how we internally evaluate the operating performance of our business units, or segments. Our operations are confined to one business segment: the development of novel drugs.
Stock-based Compensation	Stock-based Compensation  We recognize non-cash expense for the fair value of all stock options and other share-based awards. We use the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. For options granted to employees and directors, we recognize the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four years. For options granted to non-employees, we remeasure the fair value expense using Black-Scholes each reporting period.  We have granted share-based awards that vest upon achievement of certain performance criteria, or Performance Awards. We multiply the number of Performance Awards by the fair market value of our common stock on the date of grant to calculate the fair value of each award. We estimate an implicit service period for achieving performance criteria for each award. We recognize the resulting fair value as expense over the implicit service period when we conclude that achieving the performance criteria is probable. We periodically review and update as appropriate our estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.
Net Loss per Share	Net Loss per Share  Basic net loss per share is computed on the basis of the weighted-average number of common shares outstanding for the reporting period. Diluted net loss per share is computed on the basis of the weighted-average number of common shares outstanding plus dilutive potential common shares outstanding using the treasury-stock method. Potential dilutive common shares consist of outstanding equity awards and warrants. The numerators and denominators in the calculation of basic and diluted net loss per share were as follows (in thousands):     Years ended December 31,  2017 2016  Numerator:  Net loss $ (11,911) $ (14,850)  Denominator:  Shares used in computing net loss per share, basic and diluted 6,537 6,520  Net loss per share, basic and diluted $ (1.82) $ (2.28)  Dilutive common shares excluded from net loss per share, diluted 2,497 2,535   We excluded weighted equity awards outstanding to purchase common stock from the calculation of diluted net loss per share because the effect of including these shares in this calculation would be anti-dilutive.
Income Taxes	Income Taxes  We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income or loss for each full fiscal year.  We have accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. We are uncertain about the timing and amount of any future earnings. Accordingly, we offset these deferred tax assets with a valuation allowance.  We may in the future determine that certain deferred tax assets will likely be realized, in which case we will reduce our valuation allowance in the period in which such determination is made. If the valuation allowance is reduced, we may recognize a benefit from income taxes in our Statement of Operations in that period.  We classify interest recognized pursuant to our deferred tax assets as interest expense, when appropriate.
Recent Accounting Pronouncements	Recent Accounting Pronouncements  We reviewed recently issued accounting pronouncements and plan to adopt those that are applicable to us. We do not expect the adoption of these pronouncements to have a material impact on our financial position, results of operations or cash flows.  In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments . This ASU provides guidance on statement of cash flows presentation for eight specific cash flow issues where diversity in practice exists. This ASU is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company expects that the adoption will not have a material impact on its financial statements.  In February 2016, the FASB issued ASU No. 2016-02 , Leases (Topic 842) . The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For operating leases, a lessee is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in the statement of financial position. This ASU is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is evaluating the effect that the adoption of this ASU will have on its financial statements. The Company currently expects that its operating lease commitment will be subject to the new standard and recognized as right-of-use asset and operating lease liability upon adoption of ASU 2016-02, which will increase the total assets and total liabilities that it reports relative to such amounts prior to adoption. 

Summary Of Significant Accoun18

Summary Of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share	   Years ended December 31,  2017 2016  Numerator:  Net loss $ (11,911) $ (14,850)  Denominator:  Shares used in computing net loss per share, basic and diluted 6,537 6,520  Net loss per share, basic and diluted $ (1.82) $ (2.28)  Dilutive common shares excluded from net loss per share, diluted 2,497 2,535  

Cash And Cash Equivalents And19

Cash And Cash Equivalents And Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2017
Cash And Cash Equivalents And Marketable Securities [Abstract]
Cash, Cash Equivalents And Marketable Securities	   Cash, Cash Equivalents and Marketable Securities  Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Accrued Interest Total Value  December 31, 2017  Cash $ 158 $ — $ — $ 158 $ — $ 158  Cash equivalents 10,321 — — 10,321 — 10,321  Total cash and cash equivalents $ 10,479 $ — $ — $ 10,479 $ — $ 10,479  Reported as:  Cash and cash equivalents $ 10,479 — — $ 10,479 $ — $ 10,479  Marketable securities — — — — — —  $ 10,479 $ — $ — $ 10,479 $ — $ 10,479  Maturities:  Matures in one year or less $ 10,479 $ — $ — $ 10,479 $ — $ 10,479  Matures one to three years — — — — — —  $ 10,479 $ — $ — $ 10,479 $ — $ 10,479   December 31, 2016  Cash $ 1,434 $ — $ — $ 1,434 $ — $ 1,434  Cash equivalents 12,783 — — 12,783 — 12,783  Commercial paper 4,497 — — 4,497 — 4,497  Total cash and cash equivalents $ 18,714 $ — $ — $ 18,714 $ — $ 18,714  Reported as:  Cash and cash equivalents $ 16,615 — — $ 16,615 $ — $ 16,615  Marketable securities 2,099 — — 2,099 — 2,099  $ 18,714 $ — $ — $ 18,714 $ — $ 18,714  Maturities:  Matures in one year or less $ 18,714 $ — $ — $ 18,714 $ — $ 18,714  Matures one to three years — — — — — —  $ 18,714 $ — $ — $ 18,714 $ — $ 18,714  
Assets Measured At Fair Value On Recurring Basis	   Level 1 Level 2 Level 3 Total  December 31, 2017  Cash and cash equivalents $ 10,479 $ — $ — $ 10,479  Commercial paper — — — —  $ 10,479 $ — $ — $ 10,479  December 31, 2016  Cash and cash equivalents $ 14,217 $ — $ — $ 14,217  Commercial paper — 4,497 — 4,497  $ 14,217 $ 4,497 $ — $ 18,714  

Stockholders' Equity And Stoc20

Stockholders' Equity And Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity And Stock-Based Compensation [Abstract]
Stock Option Activity	  Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value  In years In millions  Outstanding as of December 31, 2016 2,435,249 $ 25.19 4.8 $ —  Options granted 1,026,410 $ 3.68  Options exercised — $ —  Options forfeited/canceled (479,504) 31.73  Outstanding as of December 31, 2017 2,982,155 $ 16.74 6.2 $ 0.4  Vested and expected to vest at December 31, 2017 2,982,155 $ 16.74 6.2 $ 0.4  Exercisable at December 31, 2017 1,757,688 $ 24.02 4.1 $ —  
Information About Stock Options Outstanding	  Options outstanding Options exercisable  Weighted  average Weighted Weighted  Number of remaining average Number of average  Range of exercise prices outstanding contractual exercise vested exercise  From To options life (in years) price options price  $ 3.24 $ 4.09 933,200 9.8 $ 3.59 46,458 $ 3.25  $ 4.10 $ 15.61 620,243 7.5 $ 11.63 345,168 $ 12.51  $ 16.31 $ 23.38 628,411 3.9 $ 19.05 597,399 $ 19.16  $ 23.59 $ 35.00 656,841 2.9 $ 30.41 626,841 $ 30.24  $ 36.40 $ 53.55 143,460 3.4 $ 51.66 141,822 $ 51.82  2,982,155 6.2 $ 16.74 1,757,688 $ 24.02 
Weighted Average Fair Value Of Options Granted	  2017 2016  Volatility 79% to 83% 72%  Risk-free interest rates 2% to 2.4% 1% to 2%  Expected life of option 7 years 7 years  Dividend yield zero zero  Forfeiture rate zero zero  Weighted average fair value of stock options granted $2.74 $1.60  
Performance Award activity	  Number of Performance Awards  Outstanding as of December 31, 2016 222,060  Granted —  Vested Performance Awards —  Forfeited/Canceled (69,720)  Outstanding as of December 31, 2017 152,340  
Summary Of Non-Cash Stock-Based Compensation	   Years ended December 31,  2017 2016   Research and development  Vesting of stock options $ 1,205 $ 1,313  Vesting of Performance Awards — 438  1,205 1,751  General and administrative  Vesting of stock options 1,768 2,179  Vesting of Performance Awards — 404  1,768 2,583  Total non-cash stock-based compensation expenses  Vesting of stock options 2,973 3,492  Vesting of Performance Awards — 842  $ 2,973 $ 4,334  

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Schedule Of Deferred Tax Assets And Valuation Allowance	  December 31,  2017 2016  Deferred tax assets:  Net operating loss carryforwards $ 15,600 $ 22,300  Stock-related compensation 5,300 9,100  Research & development credit carryforwards 6,400 6,200  Other 200 200  27,500 37,800  Valuation allowance (27,500) (37,800)  $ — $ —  
Schedule Of Unrecognized Tax Benefits	   2017 2016  Beginning balance $ 4,200 $ 4,000  Additions based on tax positions related to the current year 100 200  Ending balance $ 4,300 $ 4,200  

Leases And Commitments (Tables)

Leases And Commitments (Tables)	12 Months Ended
	Dec. 31, 2017
Leases And Commitments [Abstract]
Future Minimum Lease Payments	   2018 2019 2020 Total  Minimum lease payments $ 91 $ 95 $ 99 $ 285  

General And Liquidity (Narrativ

General And Liquidity (Narrative) (Details) $ / shares in Units, $ in Thousands	May 04, 2017	Dec. 31, 2017USD ($)$ / sharesshares	May 03, 2017shares	Dec. 31, 2016USD ($)shares
General And Liquidity [Abstract]
Previous consecutive business days		30 days
Per share requirement | $ / shares		$ 1
Calendar days following date of notification		180 days
Minimum consecutive business days		10 days
Reverse stock split ratio	0.1429
Shares outstanding | shares		6,595,509	46,100,000	6,591,705
Accumulated deficit | $		$ (157,399)		$ (145,488)

Summary Of Significant Accoun24

Summary Of Significant Accounting Policies (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)segment	Dec. 31, 2016USD ($)
Summary Of Significant Accounting Policies [Abstract]
Contractual maturity of a particular investment	1 year
Reduction to research and development expense | $	$ 1.4	$ 1.5
Number of business segments | segment	1
Vesting period of stock options	4 years

Summary Of Significant Accoun25

Summary Of Significant Accounting Policies (Numerators And Denominators In The Calculation Of Basic And Diluted Net Loss Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net loss	$ (11,911)	$ (14,850)
Denominator:
Shares used in computing net loss per share, basic and diluted	6,537	6,520
Net loss per share, basic and diluted	$ (1.82)	$ (2.28)
Dilutive common shares excluded from net loss per share, diluted	2,497	2,535

Cash And Cash Equivalents And26

Cash And Cash Equivalents And Marketable Securities (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)
Marketable Securities [Member]
Impairment charges on marketable securities other-than-temporary declines	$ 0

Cash And Cash Equivalents And27

Cash And Cash Equivalents And Marketable Securities (Cash, Cash Equivalents And Marketable Securities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis		$ 2,099
Cash and cash equivalents	$ 10,479	16,615	$ 31,299
Cash and cash equivalents, Short Term Investment, Amortized Cost	10,479	18,714
Cash and cash equivalents, Short Term Investment Unrealized Losses
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities		2,099
Cash and cash equivalents, Short Term Investment, Fair Value	10,479	18,714
Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities		2,099
Cash and cash equivalents, Short Term Investment, Fair Value	10,479	18,714
Cash [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash	158	1,434
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	158	1,434
Cash [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	158	1,434
Cash Equivalents [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents	10,321	12,783
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	10,321	12,783
Cash Equivalents [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	10,321	12,783
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Amortized Cost Basis		4,497
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Estimated Fair Value, Marketable securities		4,497
Commercial Paper [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Value, Marketable securities		4,497
Cash And Cash Equivalents, Reported Value [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents	10,479	16,615
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Fair Value	10,479	16,615
Cash And Cash Equivalents, Reported Value [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Fair Value	10,479	16,615
Matures In One Year Or Less [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Amortized Cost	10,479	18,714
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest
Cash and cash equivalents, Short Term Investment, Fair Value	10,479	18,714
Matures In One Year Or Less [Member] | Estimated Fair Value, Fair Value Disclosure [Member]
Schedule of Available-for-sale Securities [Line Items]
Cash and cash equivalents, Short Term Investment, Fair Value	10,479	18,714
Matures One To Three Years [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale securities, Gross Unrealized Losses
Accrued Interest

Cash And Cash Equivalents And28

Cash And Cash Equivalents And Marketable Securities (Assets Measured At Fair Value On Recurring Basis) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	$ 10,479	$ 18,714
Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	10,479	14,217
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		4,497
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	10,479	14,217
Level 1 [Member] | Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value	10,479	14,217
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		4,497
Level 2 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value		4,497
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Cash And Cash Equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value
Level 3 [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets measured at fair value

Property And Equipment (Details

Property And Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Accumulated depreciation	$ 0.8	$ 0.7
Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, purchase value	$ 1	$ 1

Stockholders' Equity And Stoc30

Stockholders' Equity And Stock-Based Compensation (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period	4 years
Dividend yield	0.00%	0.00%
Offering of common stock shares	120,000,000	120,000,000
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period	10 years
Compensation costs prior to forfeiture	$ 5.3
Weighted average remaining recognition period	3 years 2 months 12 days
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional stock compensation expense	$ 2.5
Performance Awards vested
Performance Awards [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance awards expiration date	Dec. 31, 2026
Performance Awards [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance awards expiration date	Dec. 31, 2022

Stockholders' Equity And Stoc31

Stockholders' Equity And Stock-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stockholders' Equity And Stock-Based Compensation [Abstract]
Number of Options, Outstanding as of December 31, 2016	2,435,249
Number of Options, Granted	1,026,410
Number of Options, Exercised
Number of Options, Forfeited/canceled	(479,504)
Number of Options, Outstanding as of December 31, 2017	2,982,155	2,435,249
Number of Options, Vested and expected to vest at December 31, 2017	2,982,155
Number of Options, Exercisable at December 31, 2017	1,757,688
Weighted Average Exercise Price, Outstanding as of December 31, 2016	$ 25.19
Weighted Average Exercise Price, Granted	3.68
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited/cancelled	31.73
Weighted Average Exercise Price, Outstanding as of December 31, 2017	16.74	$ 25.19
Weighted Average Exercise Price, Vested and expected to vest at December 31, 2017	16.74
Weighted Average Exercise Price, Exercisable at December 31, 2017	$ 24.02
Weighted Average Remaining Contractual Term at December 31, 2016	6 years 2 months 12 days	4 years 9 months 18 days
Weighted Average Remaining Contractual Term, Vested and expected to vest at December 31, 2017	6 years 2 months 12 days
Weighted Average Remaining Contractual Term, Exercisable at December 31, 2017	4 years 1 month 6 days
Outstanding, Aggregate Intrinsic Value at December 31, 2016	$ 0.4
Aggregate Intrinsic Value, Vested and expected to vest at December 31, 2017	$ 0.4

Stockholders' Equity And Stoc32

Stockholders' Equity And Stock-Based Compensation (Information About Stock Options Outstanding) (Details)	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of outstanding options, Options outstanding | shares	2,982,155
Weighted average remaining contractual life (in years), Options outstanding	6 years 2 months 12 days
Weighted average exercise price, Options outstanding	$ 16.74
Number of vested options, Options exercisable | shares	1,757,688
Weighted average exercise price, Options exercisable	$ 24.02
$3.24 - $4.09 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	3.24
Range of exercise prices, Maximum	$ 4.09
Number of outstanding options, Options outstanding | shares	933,200
Weighted average remaining contractual life (in years), Options outstanding	9 years 9 months 18 days
Weighted average exercise price, Options outstanding	$ 3.59
Number of vested options, Options exercisable | shares	46,458
Weighted average exercise price, Options exercisable	$ 3.25
$4.10 - $15.61 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	4.10
Range of exercise prices, Maximum	$ 15.61
Number of outstanding options, Options outstanding | shares	620,243
Weighted average remaining contractual life (in years), Options outstanding	7 years 6 months
Weighted average exercise price, Options outstanding	$ 11.63
Number of vested options, Options exercisable | shares	345,168
Weighted average exercise price, Options exercisable	$ 12.51
$16.31 - $23.38 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	16.31
Range of exercise prices, Maximum	$ 23.38
Number of outstanding options, Options outstanding | shares	628,411
Weighted average remaining contractual life (in years), Options outstanding	3 years 10 months 24 days
Weighted average exercise price, Options outstanding	$ 19.05
Number of vested options, Options exercisable | shares	597,399
Weighted average exercise price, Options exercisable	$ 19.16
$23.59 - $35.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	23.59
Range of exercise prices, Maximum	$ 35
Number of outstanding options, Options outstanding | shares	656,841
Weighted average remaining contractual life (in years), Options outstanding	2 years 10 months 24 days
Weighted average exercise price, Options outstanding	$ 30.41
Number of vested options, Options exercisable | shares	626,841
Weighted average exercise price, Options exercisable	$ 30.24
$36.40 - $53.55 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of exercise prices, Minimum	36.40
Range of exercise prices, Maximum	$ 53.55
Number of outstanding options, Options outstanding | shares	143,460
Weighted average remaining contractual life (in years), Options outstanding	3 years 4 months 24 days
Weighted average exercise price, Options outstanding	$ 51.66
Number of vested options, Options exercisable | shares	141,822
Weighted average exercise price, Options exercisable	$ 51.82

Stockholders' Equity And Stoc33

Stockholders' Equity And Stock-Based Compensation (Weighted Average Fair Value Of Options Granted) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stockholders' Equity And Stock-Based Compensation [Abstract]
Volatility		72.00%
Volatility, Minimum	79.00%	72.00%
Volatility, Maximum	83.00%
Risk-free interest rates, Minimum	2.00%	1.00%
Risk-free interest rates, Maximum	2.40%	2.00%
Expected life of option	7 years	7 years
Dividend yield	0.00%	0.00%
Forfeiture rate	0.00%	0.00%
Weighted average fair value of stock options granted	$ 2.74	$ 1.60

Stockholders' Equity And Stoc34

Stockholders' Equity And Stock-Based Compensation (Performance Award activity) (Details) - Performance Awards [Member]	12 Months Ended
	Dec. 31, 2017shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding as of December 31, 2016	222,060
Vested Performance Awards
Forfeited/cancelled	(69,720)
Outstanding as of December 31, 2017	152,340

Stockholders' Equity And Stoc35

Stockholders' Equity And Stock-Based Compensation (Summary Of Non-Cash Stock-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense	$ 2,973	$ 4,334
Research And Development [Member]
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense	1,205	1,751
General And Administrative [Member]
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense	1,768	2,583
Stock Options [Member]
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense	2,973	3,492
Stock Options [Member] | Research And Development [Member]
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense	1,205	1,313
Stock Options [Member] | General And Administrative [Member]
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense	$ 1,768	2,179
Performance Awards [Member]
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense		842
Performance Awards [Member] | Research And Development [Member]
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense		438
Performance Awards [Member] | General And Administrative [Member]
Stock-Based Compensation [Line Items]
Share-Based Compensation Expense		$ 404

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
U.S. federal corporate tax rate	21.00%	35.00%
Valuation allowance increase (decrease)	$ 10.3	$ 3.6
ASU 2016-09 [Member]
Operating Loss Carryforwards [Line Items]
Valuation allowance increase (decrease)	0.9
Federal [Member]
Operating Loss Carryforwards [Line Items]
Pre-tax net operating loss carryforwards	74
Federal research and development tax credits	$ 10.7
Federal [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date of pre-tax net operating loss carryforwards	Jan. 1, 2029
Expiration date of federal research and development tax credits	Jan. 1, 2023
Federal [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Expiration date of pre-tax net operating loss carryforwards	Jan. 1, 2036
Expiration date of federal research and development tax credits	Jan. 1, 2036

Income Taxes (Schedule Of Defer

Income Taxes (Schedule Of Deferred Tax Assets And Valuation Allowance) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Net operating loss carryforwards	$ 15,600	$ 22,300
Stock-related compensation	5,300	9,100
Research & development credit carryforwards	6,400	6,200
Other	200	200
Total deferred tax assets	27,500	37,800
Valuation allowance	(27,500)	(37,800)
Net deferred tax assets

Income Taxes (Schedule Of Unrec

Income Taxes (Schedule Of Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Abstract]
Beginning balance	$ 4,200	$ 4,000
Additions based on tax positions related to the current year	100	200
Ending Balance	$ 4,300	$ 4,200

Leases And Commitments (Narrati

Leases And Commitments (Narrative) (Details) $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)ft²	Dec. 31, 2016USD ($)
Leases And Commitments [Line Items]
Office space | ft²	6,000
Rent expense | $	$ 0.1	$ 0.1
Austin, TX [Member]
Leases And Commitments [Line Items]
Operating lease expiration year	2020-12

Leases And Commitments (Future

Leases And Commitments (Future Minimum Lease Payments) (Details) $ in Thousands	Dec. 31, 2017USD ($)
Leases And Commitments [Abstract]
Minimum lease payments, 2018	$ 91
Minimum lease payments, 2019	95
Minimum lease payments, 2020	99
Total	$ 285